Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
Kronos Bio (KRON) will present preclinical data from its p300 KAT inhibitor program for multiple myeloma at the ASH Annual Meeting in San Diego from December 7-10, 2024. The presentation focuses on KB-9558, their p300 KAT inhibitor being studied for multiple myeloma and HPV-driven tumors.
The research demonstrates a strong relationship between transcription factor IRF4 and p300, a protein affecting cancer cell genes. The findings show these components have a preferential protein-protein interaction through a statistically similar network of interactors, unique among tested transcription factors.
The poster presentation, scheduled for December 9, 2024, will be available on Kronos Bio's website under Publications.
Kronos Bio (KRON) presenterà dati preclinici del suo programma di inibitori p300 KAT per il mieloma multiplo durante il Meeting Annuale ASH a San Diego dal 7 al 10 dicembre 2024. La presentazione si concentra su KB-9558, il loro inibitore p300 KAT in fase di studio per il mieloma multiplo e i tumori guidati da HPV.
La ricerca dimostra una forte relazione tra il fattore di trascrizione IRF4 e p300, una proteina che influisce sui geni delle cellule cancerose. I risultati mostrano che questi componenti hanno un'interazione proteina-proteina preferenziale attraverso una rete di interattori statisticamente simile, unica tra i fattori di trascrizione testati.
La presentazione del poster, prevista per il 9 dicembre 2024, sarà disponibile sul sito web di Kronos Bio sotto Pubblicazioni.
Kronos Bio (KRON) presentará datos preclínicos de su programa de inhibidores p300 KAT para el mieloma múltiple en la Reunión Anual ASH en San Diego del 7 al 10 de diciembre de 2024. La presentación se centra en KB-9558, su inhibidor p300 KAT que se estudia para el mieloma múltiple y para tumores impulsados por HPV.
La investigación demuestra una fuerte relación entre el factor de transcripción IRF4 y p300, una proteína que afecta los genes de las células cancerosas. Los hallazgos muestran que estos componentes tienen una interacción preferente proteína-proteína a través de una red de interactores estadísticamente similar, única entre los factores de transcripción probados.
La presentación del cartel, programada para el 9 de diciembre de 2024, estará disponible en el sitio web de Kronos Bio en la sección de Publicaciones.
Kronos Bio (KRON)는 2024년 12월 7일부터 10일까지 샌디에고에서 열리는 ASH 연례 회의에서 다발성 골수종에 대한 p300 KAT 억제제 프로그램의 전임상 데이터를 발표할 예정입니다. 발표는 다발성 골수종과 HPV로 유도된 종양에 대해 연구되고 있는 p300 KAT 억제제 KB-9558에 중점을 두고 있습니다.
연구는 전사 인자 IRF4와 암세포 유전자에 영향을 미치는 단백질 p300 간의 강한 관계를 증명합니다. 연구 결과는 이러한 구성 요소가 통계적으로 유사한 상호작용 네트워크를 통해 선호하는 단백질-단백질 상호작용을 갖고 있음을 보여주며, 이는 테스트된 전사 인자 중에서 독특합니다.
올해 12월 9일로 예정된 포스터 발표는 Kronos Bio 웹사이트의 출판물 섹션에서 확인할 수 있습니다.
Kronos Bio (KRON) présentera des données précliniques de son programme d'inhibiteurs p300 KAT pour le myélome multiple lors de la Réunion Annuelle ASH à San Diego du 7 au 10 décembre 2024. La présentation se concentre sur KB-9558, leur inhibiteur p300 KAT étudié pour le myélome multiple et les tumeurs provoquées par le HPV.
La recherche démontre une forte relation entre le facteur de transcription IRF4 et p300, une protéine influençant les gènes des cellules cancéreuses. Les résultats montrent que ces composants ont une interaction protéine-protéine préférentielle à travers un réseau d'interacteurs statistiquement similaire, unique parmi les facteurs de transcription testés.
La présentation du poster, prévue pour le 9 décembre 2024, sera disponible sur le site Web de Kronos Bio dans la section Publications.
Kronos Bio (KRON) wird beim ASH-Jahrestreffen in San Diego vom 7. bis 10. Dezember 2024 präklinische Daten aus seinem p300 KAT-Inhibitorprogramm für multiples Myelom präsentieren. Der Vortrag konzentriert sich auf KB-9558, ihren p300 KAT-Inhibitor, der für multiples Myelom und HPV-getriebene Tumoren untersucht wird.
Die Forschung zeigt eine starke Beziehung zwischen Transkriptionsfaktor IRF4 und p300, einem Protein, das die Gene von Krebszellen beeinflusst. Die Ergebnisse zeigen, dass diese Komponenten eine bevorzugte Protein-Protein-Interaktion durch ein statistisch ähnliches Netzwerk von Interaktoren aufweisen, das unter den getesteten Transkriptionsfaktoren einzigartig ist.
Die Posterpräsentation, die für den 9. Dezember 2024 geplant ist, wird auf der Website von Kronos Bio unter Veröffentlichungen verfügbar sein.
- None.
- None.
– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma –
– Poster presentation to take place on Monday, December 9, 2024 –
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for multiple myeloma at the American Society of Hematology (ASH) Annual Meeting taking place in San Diego, California from December 7 to 10, 2024.
Kronos Bio is exploring the utility of its p300 KAT inhibitor, KB-9558, for multiple myeloma as well as HPV-driven tumors. In the presentation of preclinical data from the multiple myeloma program, the authors show that a context-specific and strong relationship exists between transcription factor interferon regulatory factor 4 (IRF4) and p300, a protein that impacts genes that are linked to cancer cell proliferation and survival. Furthermore, IRF4 and p300 display a preferential protein-protein interaction via a statistically similar network of interactors which was not evident with other transcription factors tested.
Abstract details are as follows:
Title: Multi-Omic Transcription Regulatory Network Mapping Identifies Targetable Oncogenic TF-Cofactor Relationship between IRF4 and p300 in Multiple Myeloma, and Is Used to Improve TF Protein-Protein
Interaction Methodology
Presenters: W. Frank Lenoir, Ph.D., Senior Scientist, Computational Biology, Bioinformatics; Charles Lin, Ph.D., Chief Scientific Officer
Poster Session: Chemical Biology and Experimental Therapeutics: Poster III
Presentation Date/Time: Monday, December 9, 2024, from 6:00 p.m. to 8:00 p.m. PST
The poster presentation will be available under the Publications section of the Kronos Bio website on December 9, 2024. The abstract can be found on the ASH Annual Meeting website.
About Kronos Bio
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapeutics that address deregulated transcription, a hallmark of cancer and autoimmune disease. Our proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors. We screen for and optimize small molecules that target these cofactors in a disease-specific context. Kronos Bio has a pipeline of three drug candidates. Istisociclib (KB-0742) is currently enrolling ovarian cancer patients in a Phase 1/2 clinical trial. Preclinical candidate KB-9558 is being developed for multiple myeloma and HPV-driven tumors. KB-7898 is Kronos Bio’s first autoimmune development candidate and has a target indication of Sjögren’s disease. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com or follow the Company on LinkedIn.
FAQ
What will Kronos Bio (KRON) present at the 2024 ASH Annual Meeting?
When and where will Kronos Bio (KRON) present at ASH 2024?
What are the key findings in Kronos Bio's (KRON) multiple myeloma research?
What conditions is Kronos Bio's (KRON) KB-9558 being studied for?
